Literature DB >> 11940544

Pulmonary hypertension and risk of death in cardiomyopathy: patients with myocarditis are at higher risk.

Thomas P Cappola1, G Michael Felker, W H Linda Kao, Joshua M Hare, Kenneth L Baughman, Edward K Kasper.   

Abstract

BACKGROUND: Pulmonary hypertension is a clinically useful predictor of death in patients with heart failure. Whether pulmonary hypertension has the same prognostic value among specific underlying causes of cardiomyopathy is unknown. Using a diverse cohort of cardiomyopathy patients, we tested the hypotheses that (1) elevated mean pulmonary arterial pressure is the most important hemodynamic predictor of death and (2) the prognostic value of mean pulmonary pressure varies among different cardiomyopathies. METHODS AND
RESULTS: Patients (n=1134) with new cardiomyopathy were prospectively assigned a specific diagnosis on the basis of clinical evaluation and endomyocardial biopsy. All patients underwent right heart catheterization at baseline and were followed for an average of 4.4 years. In multivariate Cox models that allowed for nonlinear relations between hemodynamics and death, mean systemic pressure (mSP) and mean pulmonary arterial pressure (mPA) emerged as the most important hemodynamic predictors of death. Moreover, there was a statistically significant positive interaction between mPA and the diagnosis of myocarditis. For each 5-mm Hg increase in baseline mSP, mortality rates decreased with relative hazard (RH) of 0.89 (0.86 to 0.92). For a 5-mm Hg increase in baseline mPA, mortality rates increased in patients who did not carry the diagnosis of myocarditis with RH 1.23 (1.17 to 1.29); among patients with myocarditis, mortality rates increased substantially with RH of 1.85 (1.50 to 2.29; P<0.001 for interaction).
CONCLUSIONS: Baseline mPA is particularly important for stratifying risk in myocarditis. These findings suggest that secondary pulmonary hypertension may have different biological features in myocarditis and that patients with pulmonary hypertension and myocarditis should be targeted for aggressive medical therapy.

Entities:  

Mesh:

Year:  2002        PMID: 11940544     DOI: 10.1161/01.cir.0000013771.30198.82

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  32 in total

1.  What is the prognostic significance of pulmonary hypertension in heart failure?

Authors:  Neal A Chatterjee; Gregory D Lewis
Journal:  Circ Heart Fail       Date:  2011-09       Impact factor: 8.790

Review 2.  Pulmonary Hypertension Due to Left Heart Disease: an Update.

Authors:  Mandar A Aras; Mitchell A Psotka; Teresa De Marco
Journal:  Curr Cardiol Rep       Date:  2019-05-27       Impact factor: 2.931

3.  Peritoneal ultrafiltration in refractory heart failure: a cohort study.

Authors:  Silvio V Bertoli; Claudio Musetti; Daniele Ciurlino; Carlo Basile; Emilio Galli; Giovanni Gambaro; Gianmaria Iadarola; Carlo Guastoni; Antonio Carlini; Federica Fasciolo; Maurizio Borzumati; Maurizio Gallieni; Farina Stefania
Journal:  Perit Dial Int       Date:  2013-10-31       Impact factor: 1.756

4.  Pulmonary Arterial Capacitance Is an Important Predictor of Mortality in Heart Failure With a Preserved Ejection Fraction.

Authors:  Nadine Al-Naamani; Ioana R Preston; Jessica K Paulus; Nicholas S Hill; Kari E Roberts
Journal:  JACC Heart Fail       Date:  2015-06       Impact factor: 12.035

Review 5.  Treatment and Prognosis of Pulmonary Hypertension in the Left Ventricular Assist Device Patient.

Authors:  Christopher W Jensen; Andrew B Goldstone; Y Joseph Woo
Journal:  Curr Heart Fail Rep       Date:  2016-06

Review 6.  Cardiac energy metabolic alterations in pressure overload-induced left and right heart failure (2013 Grover Conference Series).

Authors:  Sowndramalingam Sankaralingam; Gary D Lopaschuk
Journal:  Pulm Circ       Date:  2015-03       Impact factor: 3.017

7.  Gender Differences in Prognostic Markers of All-Cause Death in Patients with Acute Heart Failure: a Prospective 18-Month Follow-Up Study.

Authors:  Xiaoting Wu; Mengli Chen; Kai Wang; Rongrong Gao; Xinli Li
Journal:  J Cardiovasc Transl Res       Date:  2019-05-22       Impact factor: 4.132

Review 8.  Pulmonary Hypertension in Heart Failure Patients: Pathophysiology and Prognostic Implications.

Authors:  Marco Guazzi; Valentina Labate
Journal:  Curr Heart Fail Rep       Date:  2016-12

9.  Approach to patients with heart failure and pulmonary hypertension.

Authors:  Paul R Forfia
Journal:  Curr Treat Options Cardiovasc Med       Date:  2007-08

10.  Management of severe pulmonary hypertension in patients undergoing mitral valve surgery.

Authors:  Carlos D Davila; Paul R Forfia
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.